We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-0.04%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$304M
AUM Growth
+$1.15M
Cap. Flow
+$57.5M
Cap. Flow %
18.92%
Top 10 Hldgs %
41.92%
Holding
84
New
27
Increased
13
Reduced
15
Closed
15

Top Buys

1
KRYS icon
Krystal Biotech
KRYS
+$7.32M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$4.48M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$4.42M
4
SLRN
ACELYRIN
SLRN
+$4.25M
5
AMAM
Ambrx Biopharma Inc
AMAM
+$3.91M

Top Sells

1
AKRO
Akero Therapeutics
AKRO
+$11.4M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$8.67M
3
APLS
Apellis Pharmaceuticals
APLS
+$7.91M
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$7.08M
5
PCVX icon
Vaxcyte
PCVX
+$6.91M

Sector Composition

1 Healthcare 67.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
76
PTC Therapeutics
PTCT
$6.52B
– –
-16,675
Closed -$678K
RCKT icon
77
Rocket Pharmaceuticals
RCKT
$376M
– –
-75,000
Closed -$1.36M
REPL icon
78
Replimune Group
REPL
$859M
– –
-10,865
Closed -$213K
SWTX
79
DELISTED
SpringWorks Therapeutics
SWTX
– –
-27,578
Closed -$723K
VIR icon
80
Vir Biotechnology
VIR
$1.59B
– –
-150,000
Closed -$3.68M
VNDA icon
81
Vanda Pharmaceuticals
VNDA
$327M
– –
-31,000
Closed -$204K
ONC
82
BeOne Medicines Ltd
ONC
$32.4B
– –
-22,500
Closed -$4.01M
MORF
83
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-20,000
Closed -$1.15M
RETA
84
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-85,000
Closed -$8.67M
1 2 3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Ghost Tree Capital held 84 positions worth $304M, up 0.38% from $303M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ghost Tree Capital deployed $57.5M of net new capital in Q3 2023, opening 27 new positions and adding to 13 existing holdings. Its largest new stake was Deciphera Pharmaceuticals, Inc. Common Stock: 325,000 shares worth $4.13M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 91% a quarter earlier.

On the sell side, the largest reduction was Akero Therapeutics, an estimated $11.4M trimmed.

  • Ghost Tree Capital's largest Q3 2023 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 325,000 shares worth $4.13M.
  • Ghost Tree Capital added most to Krystal Biotech in Q3 2023, an estimated $7.32M increase.
  • Ghost Tree Capital's biggest Q3 2023 reduction was Akero Therapeutics, cutting an estimated $11.4M.
  • Ghost Tree Capital fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $8.67M.
  • Ghost Tree Capital's ten largest holdings make up 42% of its $304M portfolio in Q3 2023.
  • Ghost Tree Capital opened 27 new positions and closed 15 in Q3 2023.
  • Ghost Tree Capital's portfolio value rose 0.38% quarter-over-quarter to $304M.

Based on Ghost Tree Capital's 13F filing for Q3 2023, filed 14 Nov 2023.